Mechano-Growth Factor (MGF) and Insulin-Like Growth Factor-1 (IGF-1) research encompasses the investigation of alternative splicing, post-translational modifications, and tissue-specific functions of ...
A recent study published in Current Molecular Pharmacology highlights the potential of insulin-like growth factor binding ...
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today ...
A subcutaneous monoclonal antibody induced greater reductions in proptosis at 24 weeks than placebo for people with active ...
Viridian Therapeutics issued a press release that announced the positive elegrobart topline results from the phase 3 REVEAL-1 ...
Elegrobart is a subcutaneously-administered monoclonal antibody designed to target and inhibit the IGF-1 receptor, a key driver of thyroid eye disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results